EC GRANTS MARKETING AUTHORIZATION TO ACOMPLIA

French drugmaker sanofi-aventis has announced that the European Commission (EC) has granted marketing authorization for Acomplia (rimonabant 20 mg/day) in all 25 European member states.

Acomplia, discovered and developed by sanofi-aventis, is the first in a new class of drugs called CB blockers. It is indicated as an adjunct to diet and exercise for the treatment of obese patients, or overweight patients with associated risk factors, such as Type 2 diabetes or dyslipidaemia.